ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.

GlobeNewsWire • Nov 26, 2025

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-cost profile is driving adoption, with growing prescriber base and international launches, but long-term profitability remains uncertain.

Seeking Alpha • Nov 10, 2025

ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Director Eric Karas - Chief Commercial Officer Kathleen Scott - Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Kevin Holder - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning and welcome to ARS Pharmaceuticals Conference Call.

Seeking Alpha • Nov 10, 2025

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025

GlobeNewsWire • Nov 10, 2025

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.

Zacks Investment Research • Nov 10, 2025

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Offers no-hassle, free  virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may already have an auto-injector, but are looking for a smaller, easier to administer option SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced the launch of “Get  neffy on Us,” a new integrated commercial program to help patients access their needle-free epinephrine medicine, neffy . Get neffy on Us was created to eliminate the time burden of an in-person office visit by offering a free visit with a virtual provider who can prescribe neffy.

GlobeNewsWire • Nov 4, 2025

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m.

GlobeNewsWire • Nov 3, 2025

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray)

GlobeNewsWire • Nov 3, 2025

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation to report results from real world data on the effectiveness of epinephrine nasal spray in clinical practice Case reports to detail real-world data and effective use of neffy in patients who experience anaphylaxis during oral food challenges or allergy immunotherapy SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that one late-breaking oral and six poster presentations will be featured at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place November 6-10, 2025, in Orlando, FL. The presentations highlight real-world experience associated with intranasal epinephrine.

GlobeNewsWire • Nov 3, 2025

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the Opposition Division of the European Patent Office (the “EPO”) upheld the validity of all claims in EP 3678649, which is a patent validated in over 30 European countries directed to nasal spray epinephrine formulations including alkyl-glycoside, such as Intravail®, and uses thereof. ARS Pharma's issued global intellectual property portfolio related to neffy provides coverage until at least 2039.

GlobeNewsWire • Oct 8, 2025